Clinical trials: Metastatic Liver Disease
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Colorectal Cancer, MSS
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091.
- Conditions
- Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- KISIMA-01 (NCT04046445)
- Testing
- ATP128, BI 754091, VSV-GP128
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 96 people
- Sponsor
- Amal Therapeutics
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Colo-rectal Cancer, Liver Metastases
Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis
The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico…
- Conditions
- Colo-rectal Cancer, Liver Metastases, Colon Cancer
- Trial name
- RaP-DMac-LiMe (NCT07744139)
- Testing
- Radiogenomic and Immune Profiling, Prospective Radiogenomic and ctDNA Profiling
- Volunteers
- 210 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma, Neuroendocrine Tumors
EchoTip AcuCore Post-Market Clinical Study
The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the…
- Conditions
- Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT06358001
- Testing
- EchoTip AcuCore
- Where
- 8 sites in United States
- Volunteers
- 183 people
- Sponsor
- Cook Research Incorporated
Liver Neoplasms, Neoplasm Metastasis
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan.
- Trial name
- NCT00001587
- Testing
- Isolated hepatic portal and arterial perfusion, Melphalan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00658593
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 8 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer, Colon Cancer Liver Metastasis
Diffusion-Weighted MRI for Liver Metastasis
The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM)…
- Conditions
- Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
- Trial name
- DREAM (NCT02781935)
- Testing
- DW-MRI
- Where
- 21 sites in United States, Austria and 3 more
- Volunteers
- 233 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Stage IV Melanoma
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.
- Trial name
- DEBDOX (NCT01010984)
- Testing
- LC beads loaded with Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Robert C. Martin
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
BACKGROUND: For patients with liver-limited metastatic colorectal cancer (mCRC), complete resection of liver metastases is the only potentially curative treatment.
- Trial name
- FORBES (NCT02350530)
- Testing
- FOLFOXIRI + Bevacizumab, FOLFOXIRI
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer
- Trial name
- NCT00026234
- Testing
- floxuridine, dexamethasone, oxaliplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer
Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients
The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer.
- Trial name
- NCT06999252
- Testing
- Rimegepant, PD-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
This phase II trial tests how well cemiplimab and transarterial radioembolization (TARE) with yttrium-90 (Y90) SIR-Spheres, registered trademark, works in treating breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
- Trial name
- NCT06860815
- Testing
- Biopsy, Biospecimen Collection, Cemiplimab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma, Hepatocellular Cancer
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03785210
- Testing
- nivolumab, tadalafil, oral vancomycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Intraocular Melanoma, Metastatic Cancer
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00110123
- Testing
- fotemustine, isolated perfusion
- Where
- 8 sites in Italy, Poland and 2 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Liver Cancer
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
An open label multi-site phase II clinical trial of dose escalated sunitinib malate given orally once daily on days 1-28 of each 42-day cycle.
- Trial name
- NCT00495625
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma
This study is an open-label, Phase Ib clinical study to evaluate Evaluate the Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection…
- Trial name
- NCT04206358
- Testing
- OrienX010 combination with JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.